Pharmacologic approaches to radiation protection

Area of Science:

• Oncology
• Radiotherapy
• Pharmacology

Background:

• The therapeutic ratio (TR) is crucial for radiotherapy efficacy, balancing tumor control and normal tissue toxicity.
• Ideal radioprotectors enhance the TR by minimizing radiation-induced injury without compromising anti-tumor effects.
• Current radioprotective approaches are categorized into protection, mitigation, and treatment.

Purpose of the Study:

• To elucidate the concept of the therapeutic ratio (TR) in radiotherapy.
• To outline different categories of radioprotective strategies and their mechanisms.
• To emphasize the importance of integrating pharmacologic and physical strategies for optimal clinical outcomes.

Main Methods:

• Conceptual review of radioprotective strategies.
• Classification of radioprotectors based on administration timing and function.
• Discussion of prototype drugs like amifostine and palifermin.
• Integration of radioprotective concepts with advanced radiotherapy techniques like intensity-modulated radiotherapy (IMRT).

Main Results:

• Radioprotectors are essential for improving the therapeutic ratio (TR).
• Protection strategies (e.g., amifostine) are administered before radiotherapy to prevent injury.
• Mitigation strategies (e.g., palifermin) are used post-radiotherapy to ameliorate damage.
• Treatment strategies are primarily palliative and supportive.

Conclusions:

• Optimizing the therapeutic ratio is key to effective radiotherapy.
• Pharmacologic radioprotectors, when classified as protectors or mitigants, offer distinct clinical benefits.
• The maximal clinical potential of radioprotective agents is realized through integration with advanced physical techniques such as intensity-modulated radiotherapy.